Table 2. Selected demographic, clinical, and biochemical, characteristics of 86 patients with NAFLD without NASH and univariate analysis by presence of significant liver fibrosis.
| Variable | Significant liver fibrosis (n = 12) | No significant liver fibrosis (n = 74) |
|---|---|---|
| Age (mean years, SD) | 55.7 (10.1) | 52.1 (9.32) |
| Male gender (%) | 9 (75.0) | (81.9) |
| White/Caucasian Ethnicity (%) | 10 (83.3) * | 35 (47.3) * |
| Diabetes (%) | 2 (16.7) | 6 (8.1) |
| BMI (mean Kg/m2, SD) | 27.3 (2.6) | 27.7 (4.3) |
|
Time since HIV diagnosis (mean years, SD) |
15.5 (8.9) | 13.9 (7.5) |
| Nadir CD4 count | 320.5 (329.3) | 251.6 (200.4) |
| Current ART regimen (%) | ||
| PI | 5 (41.7) | 26 (35.1) |
| NNRTI | 3 (25.0) | 27 (36.5) |
| NRTI | 10 (83.3) | 61 (82.4) |
| Integrase inhibitor | 3 (25.0) | 23 (31.1) |
|
Platelet count (mean 109/L, SD) |
208.2 (57.9) | 216.4 (59.7) |
| ALT (mean U/L, SD) | 35.8 (17.3) * | 25.5 (11.2) * |
| HOMA-IR (SD) | 4.5 (3.8) * | 3.1 (3.4) * |
|
Total Cholesterol (mean mmol/L, SD) |
4.9 (1.1) | 5.0 (1.0) |
|
Triglycerides (mean mmol/L, SD) |
1.5 (0.6) | 2.1 (1.6) |
Significant liver fibrosis was defined as LSM >7.1 kPa. Continuous variables are expressed as mean (SD) and categorical variables were presented as numbers (%).
* p < 0.05.
p-values refer to T-test or chi-squared test between patients with and without significant liver fibrosis. HOMA-IR was evaluated in 59 patients.
Abbreviations; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; ART, antiretroviral therapy; GGT, gamma-glutamyl transpeptidase; HIV, human immunodeficiency virus; HOMA-IR, homeostasis model for assessment of insulin resistance; IDU, injection drug use; IU, international units; LSM, liver stiffness measurement; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, Protease Inhibitors; SD, standard deviation.